about
Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders'As required' medication regimens for seriously mentally ill people in hospitalBenzodiazepines for psychosis-induced aggression or agitationLoxapine inhaler for psychosis-induced aggression or agitationQuetiapine for psychosis-induced aggression or agitationRisperidone for psychosis induced aggression or agitationChlorpromazine for psychosis induced aggression or agitationTrifluoperazine for schizophreniaNew generation antipsychotics for first episode schizophreniaCurrent approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatmentsChanges in body weight and psychotropic drugs: a systematic synthesis of the literature[EXPRESS] Slack KNa Channels Influence Dorsal Horn Synapses and Nociceptive Behavior.Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials.Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens.Revisiting loxapine: a systematic review.Inhaled loxapine and intramuscular lorazepam in healthy volunteers: a randomized placebo-controlled drug-drug interaction study.Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors.Benzodiazepines for psychosis-induced aggression or agitation.The in vitro actions of loxapine on dopaminergic and serotonergic receptors. Time to consider atypical classification of this antipsychotic drug?Safety and efficacy of self-administered inhaled loxapine (ADASUVE) in agitated patients outside the hospital setting: protocol for a phase IV, single-arm, open-label trial
P2860
Q24186601-5B4BEEE3-FE64-480F-BD3B-FAB30A3D7C0DQ24187005-CF68C427-E5E3-41FC-BDAC-CEF53953A100Q24197734-BAEAF10E-9A31-4065-87C6-A5FE5BDD9A84Q24197864-EB86504B-8AAA-4F81-977B-8DF149C7F4D0Q24200644-71A87FB8-04AB-4F40-82C0-E94C7D5CAB73Q24235440-6DEA7930-70A3-44AC-8F3E-46D07365A430Q24235748-1A77F3EA-37F7-446C-B78B-825EB621FFFDQ24247440-86BC2113-746D-477B-8A20-1C212E5E78DCQ24247720-41F9ECE8-1D51-42A3-9906-4CADCDB76D92Q27003099-6A311898-DFFC-4415-A88B-0BCE77E471F3Q28728401-1E21F7F2-709B-496D-B3D0-2C70A047C9A5Q33840478-C70E984B-B99C-470C-BAB5-CA161BC6FEBDQ34751469-FE2029C8-75BA-45B8-A732-29DFA96DDB88Q37268835-2A2433DF-4BD8-4249-BA0E-94452AFA5334Q38413932-6B35A680-31C1-43F6-A15D-2D81BE16B76DQ38761946-C2B1AA52-C141-4236-A915-AC8FD45B90E1Q41859643-F4632A01-2E8F-4C09-867B-4BFE427DDC23Q43945827-FC9864B2-AC03-46B9-86F9-F1D9C5D343CBQ47985236-59BAB420-93A3-47C0-BC36-3D84D4021A51Q57044328-A7CE956D-618D-42FB-8FC4-2041586E30DE
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Loxapine for schizophrenia
@ast
Loxapine for schizophrenia
@en
Loxapine for schizophrenia
@en-gb
Loxapine for schizophrenia
@nl
type
label
Loxapine for schizophrenia
@ast
Loxapine for schizophrenia
@en
Loxapine for schizophrenia
@en-gb
Loxapine for schizophrenia
@nl
prefLabel
Loxapine for schizophrenia
@ast
Loxapine for schizophrenia
@en
Loxapine for schizophrenia
@en-gb
Loxapine for schizophrenia
@nl
P2093
P2860
P1476
Loxapine for schizophrenia
@en
P2093
Abhijit Chakrabarti
Anne-Marie Bagnall
Mark Fenton
Pierre Chue
Vikram Palanisamy
Winson Wong
P2860
P356
10.1002/14651858.CD001943.PUB2
P577
2007-10-17T00:00:00Z